A new review of scientific research on the lesser-known cannabinoid cannabigerol (CBG) says the compound has the \u201cpotential to modulate multiple physiological processes,\u201d which could give it \u201ctherapeutic power to alleviate various conditions, including cancer, metabolic, pain, and inflammatory disorders, among others.\u201d<\/p>\n
\u201cCBG has emerged as a potential therapeutic agent with a diverse range of effects,\u201d says the new paper, published this month in the journal Molecules. \u201cAlthough research on CBG is still in its early stages, its unique molecular mechanism and promising therapeutic profile warrant further exploration.\u201d<\/p>\n
The research looks not only at the potential effects of CBG but also its mechanisms of action. Like delta-9 THC and CBD, it says, CBG interacts with the body\u2019s cannabinoid receptors\u2014but it also \u201chas a unique affinity for other receptors, such as the \u03b1<\/span>2AR and 5-HT1A <\/span>receptors.\u201d<\/p>\n The cannabinoid\u2019s \u201cdiverse mechanisms,\u201d the report says, \u201ctranslate into a wide range of potential therapeutic applications, including neuroprotection, anti-inflammation, antibacterial properties, hypotension, cancer treatment, pain management, and metabolic syndrome.\u201d<\/p>\n Some CBG users also report improved sleep, it adds, \u201calthough this has not yet been confirmed by clinical studies.\u201d<\/p>\n The 10-person team behind the new review includes researchers from Guangdong University of Techonology in Guangzhou, China; Cedars-Sinai Cancer Institute, in Los Angeles; the Beckman Research Institute of City of Hope, in Duarte, California; Guangzhou University of Chinese Medicine; and Sun Yat-Sen University, also in Guangzhou.<\/p>\n Authors said that while there have been \u201csome excellent reviews on CBG, discussing pharmacological potential, the bioactivity of CBD and its analogs, the biomedical relevance, and its interactions with volted-gated sodium channels,\u201d their own review differs from others in that it discusses \u201cthe molecular mechanisms of action of the therapeutic effects of CBG within different disease contexts.\u201d<\/p>\n From there, the report runs through evidence for CBG\u2019s role in various applications. It points, for example, to possibilities for neuroprotection\u2014noting potential applications for treatment of neurodegenerative diseases, including Alzheimer\u2019s disease, Parkinson\u2019s disease and multiple sclerosis\u2014noting that CBG treatment has been shown to improve motor function and reduce markers of stress in the brain.<\/p>\n Some of the reviewed studies looked at CBG in combination with other cannabinoids, authors noted, adding that \u201cstudying CBG independently from other cannabinoids could pinpoint the distinct therapeutic properties and specific mechanisms in the context of the central nervous system.\u201d<\/p>\n Regarding pain, authors pointed to evidence suggesting CBG treatment can reduce pain sensitivity in mice, noting that one possible explanation is that the cannabinoid \u201cmight make it harder for pain signals to be transmitted effectively.\u201d<\/p>\n \u201cThis research unveils a potential mechanism for CBG\u2019s indirect neuroprotective effects. By reducing pain signaling in the nervous system, CBG might offer relief from chronic pain conditions,\u201d they wrote. \u201cThis finding adds to the growing body of evidence suggesting CBG\u2019s potential role in protecting the nervous system by managing pain.\u201d<\/p>\n The report also looks at evidence for CBG\u2019s anti-inflammatory effects, which might be helpful in managing inflammatory bowel disease\u2014including Crohn\u2019s disease and ulcerative colitus\u2014rheumatoid arthritis, allergic asthma and liver injury. And it points to studies into the cannabinoid\u2019s possible antibacterial effects and role in treating hypotension or vasoconstriction.<\/p>\n Studies indicate that CBG \u201cmay disrupt the bacterial cell membrane, a crucial barrier to cell survival,\u201d authors wrote. \u201cThis disruption can lead to the leakage of essential cellular components and ultimately cell death.\u201d The cannabinoid appears to also inhibit the formation of some biofilms, communities of bacteria that can be highly resistant to antibiotics.<\/p>\n New studies are also looking at CBG in anti-cancer treatment, the paper notes, adding to a research that until recently focused on THC and CBD.<\/p>\n \u201cAccumulating evidence has substantiated the anti-tumorigenic properties of CBG, showcasing its efficacy in reducing cell proliferation, migration, and survival in various tumor types,\u201d it says, \u201cincluding prostate cancer, glioblastoma, colorectal carcinoma, pancreatic cancer, and breast cancer.\u201d<\/p>\n Combining CBG with conventional chemotherapy \u201cholds promise for enhancing treatment efficacy,\u201d the report notes, though a mix of cannabinoids may also offer benefits in some cancers.<\/p>\n Both CBG and CBD appeared to suppress prostate-cancer development in mice to some degree, for example, but \u201cthe two in combination exhibited potent anti-cancer effects even in mice unresponsive to enzalutamide (androgen receptor agonist) treatment,\u201d it explains. \u201cAs such, combination therapy may be an attractive adjuvant therapeutic option for prostate cancer models.\u201d<\/p>\n Another condition authors considered was metabolic syndrome, which is linked to the development of other ailments such as cardiovascular disease, liver disease and type 2 diabetes.<\/p>\n \u201cRecent studies on CBG provide a potential pharmacotherapy strategy for metabolic syndrome,\u201d they wrote, noting that CBG is \u201cthe sole known cannabinoid that activates the adrenergic receptor.\u201d<\/p>\n The review says CBG \u201chas been shown to reduce appetite and induce weight loss by blocking CB1 receptors\u201d and \u201cto increase the activity of brown adipose tissue (BAT), which is responsible for burning calories and generating heat. HUM-234, a derivative of CBG, has been shown to prevent high-fat diet-induced weight gain and lower serum levels of liver enzymes ALT and AST.\u201d<\/p>\n Many of the studies evaluated in the new review involved research in cells or mouse models. In many areas where CBG has shown to be promising, human trials will be crucial to moving treatment forward, the research team said.<\/p>\n \u201cAs research progresses, CBG presents as a promising therapeutic agent with a unique molecular profile and a broad spectrum of potential benefits,\u201d they wrote. \u201cAs deepen our understanding of CBG, it may lead to breakthroughs in treating complex conditions, ultimately improving patient outcomes and expanding the scope of cannabinoid-based medicine.\u201d<\/p>\n Further research, authors added, should focus not only on \u201cclinical trials, detailed mechanistic studies, and optimized delivery systems\u201d but also the its \u201csynergy with other cannabinoids and traditional medicines.\u201d<\/p>\n \u201cThe next decade could see CBG integrated into mainstream medical practice,\u201d the paper<\/a> says, \u201crevolutionizing the approach to many chronic and debilitating conditions.\u201d<\/p>\n Despite ongoing obstacles to marijuana research generally, investigation of marijuana\u2019s many chemical components has expanded considerably as the nation\u2019s war on cannabis has waned. As a separate paper published earlier this year found, \u201ca diverse array of lesser-known phytocannabinoids, along with terpenes, flavonoids, and alkaloids\u201d have been shown to \u201cdemonstrate diverse pharmacological activities\u201d<\/a> and could offer a multitude of therapeutic applications.<\/p>\n \u201cTheir antioxidant, anti-inflammatory and neuromodulatory effects position them as promising agents in treating neurodegenerative disorders,\u201d said that report, authored by a pair of researchers from the Center for Dementia Research at the Nathan Kline Institute for Psychiatric Research in New York.<\/p>\n That study followed separate research published this summer into the lesser chemical components of marijuana, which found that minor cannabinoids may have anticancer effects on blood cancer<\/a>.<\/p>\n That research, published in the journal BioFactors, looked at minor cannabinoids and multiple myeloma (MM), testing responses in cell models to the cannabinoids CBG, CBC, CBN and CBDV as well as studying CBN in a mouse model.<\/p>\n \u201cTogether, our results suggest that CBG, CBC, CBN, and CBDV can be promising anticancer agents for MM,\u201d authors wrote, \u201cdue to their cytotoxic effect on MM cell lines and, for CBN, in\u00a0in vivo\u00a0<\/em>xenograft mouse model of MM.\u201d<\/p>\n They also noted the cannabinoids\u2019 apparently \u201cbeneficial effect on the bone in terms of reduction of MM cells invasion toward the bone and bone resorption (mainly CBG and CBN).\u201d<\/p>\n A more recent study, meanwhile, found that while it\u2019s \u201cplausible\u201d that terpenes produced by cannabis are responsible for modulating a marijuana high<\/a>, it\u2019s still \u201cunproven.\u201d<\/p>\n A federally funded study published in May, meanwhile, found that terpenes could be \u201cpotential therapeutics for chronic neuropathic pain,\u201d finding that an injected dose of the compounds\u00a0produced a \u201croughly equal\u201d reduction in pain markers when compared to a smaller dose of morphine<\/a>. Terpenes also appeared to enhance the efficacy of morphine when given in combination.<\/p>\n Unlike with morphine, however, none of the studied terpenes produced a meaningful reward response, that research found, indicating that \u201cterpenes could be effective analgesics with no rewarding or dysphoric side effects.\u201d<\/p>\n Another study published earlier this year looked at the\u00a0\u201ccollaborative interactions\u201d between cannabinoids, terpenes, flavonoids and other molecules in the plant<\/a>, concluding that a better understanding of the relationships of various chemical components \u201cis crucial for unraveling cannabis\u2019s complete therapeutic potential.\u201d<\/p>\n Other recent research funded by the National Institute on Drug Abuse (NIDA) found that a citrusy-smelling terpene in marijuana, D-limonene,\u00a0could help ease anxiety and paranoia associated with THC<\/a>. Researchers similarly said the finding could help unlock the maximum therapeutic benefit of THC.<\/p>\n A separate study last year found that cannabis products\u00a0with a more diverse array of natural cannabinoids produced stronger psychoactive experiences<\/a>\u00a0in adults, which also lasted longer than the high generated by pure THC.<\/p>\n And a 2018 study found that patients suffering from epilepsy experience better health outcomes\u2014with fewer adverse side effects\u2014when they use plant-based CBD extracts compared to \u201cpurified\u201d CBD products<\/a>.<\/p>\n Scientist last year also discovered\u00a0\u201cpreviously unidentified cannabis compounds\u201d called flavorants<\/a>\u00a0that they believe are responsible for the unique aromas of different varieties of marijuana. Previously, many had thought terpenes alone were responsible for various smells produced by the plant.<\/p>\n Similar phenomena are also beginning to be recorded around psychedelic plants and fungi. In March, for example, researchers published findings showing that\u00a0use of full-spectrum psychedelic mushroom extract had a more powerful effect than chemically synthesized psilocybin alone<\/a>. They said the findings imply that mushrooms, like cannabis, demonstrate an entourage effect.<\/p>\n Marijuana Has \u2018No Significant Harmful Effects\u2019 On Age-Related Cognitive Decline, Study Shows<\/a><\/p>\n<\/blockquote>\n\n The post Lesser-Known Marijuana Component CBG Is A \u2018Promising Therapeutic Agent\u2019 With Potential To Treat Cancer And Pain, Study Says<\/a> appeared first on Marijuana Moment<\/a>.<\/p>\n
A new review of scientific research on the lesser-known cannabinoid cannabigerol (CBG) says the compound has the \u201cpotential to modulate multiple physiological processes,\u201d which could give it \u201ctherapeutic power to alleviate various conditions, including cancer, metabolic, pain, and inflammatory disorders, among others.\u201d \u201cCBG has emerged as a potential therapeutic agentContinue Reading<\/a><\/span><\/p>\n","protected":false},"author":24,"featured_media":0,"comment_status":"false","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[18,15462],"tags":[],"_links":{"self":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/79230"}],"collection":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/comments?post=79230"}],"version-history":[{"count":1,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/79230\/revisions"}],"predecessor-version":[{"id":79231,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/79230\/revisions\/79231"}],"wp:attachment":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/media?parent=79230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/categories?post=79230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/tags?post=79230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
\nRead More: Lesser-Known Marijuana Component CBG Is A \u2018Promising Therapeutic Agent\u2019 With Potential To Treat Cancer And Pain, Study Says<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"